HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) All Versions of this Article: ERC-08-0116v1 15/4/943    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, W. Articles by Habuchi, T. Search for Related Content PubMed PubMed Citation Articles by Wang, W. Articles by Habuchi, T.

W Wang, Urology, Akita University School of Medicine, Akita, Japan
T Yuasa, Urology, Akita University School of Medicine, Akita, 010-8543, Japan
N Tsuchiya, Urology, Akita University School of Medicine, Akita, Japan
S Maita, Urology, Akita University School of Medicine, Akita, Japan
T Kumazawa, Urology, Akita University School of Medicine, Akita, Japan
T Inoue, Urology, Akita University School of Medicine, Akita, Japan
M Saito, Urology, Akita University School of Medicine, Akita, Japan
Z Ma, Urology, Akita University School of Medicine, Akita, United Kingdom
T Obara, Urology, Akita University School of Medicine, Akita, Japan
H Tsuruta, Urology, Akita University School of Medicine, Akita, Japan
S Satoh, Urology, Akita University School of Medicine, Akita, Japan
T Habuchi, Urology, Akita University School of Medicine, Akita, Japan

Correspondence: Takeshi Yuasa, Email: yuasa{at}doc.med.akita-u.ac.jp

Abstract

Androgen-deprivation therapy (ADT) of patients with prostate cancer (PCa) is known to reduce bone mineral density (BMD). However, most studies examined Caucasian or black patients and the effects of ADT on the bone metabolism of East Asians are unclear. Therefore, we performed a cross-sectional study to elucidate the influence of ADT on bone metabolism in Japanese patients. In total, 101 native Japanese patients with PCa were enrolled. They consisted of 58 ADT-treated and 43 hormone-naive patients. The BMD in the lumbar spine, total hip, and femoral neck was measured by dual energy x-ray absorptiometry and expressed in standard deviation units relative to young adult men (T-score) or age-matched men (Z-score). Serum levels of bone metabolism markers were also measured. The BMDs at the three sites revealed that 2.3% (1/43) and 8.6% (5/58) of the hormone-naive and ADT-treated PCa patients had osteoporosis, respectively, but this difference failed to achieve statistical significance (P=0.294). The two groups also did not differ significantly in their Z-scores of the three sites, and univariate and multivariate analyses indicated that ADT was not a significant risk factor for decreased BMD. In addition, a significant correlation between the duration of ADT and BMD was not observed for all three sites measured. However, the ADT-treated patients had significantly higher serum levels of amino-terminal telopeptide (NTx) than the hormone-naive patients (P=0.017). To our knowledge, this is the first study to demonstrate the low prevalence of osteoporosis in both ADT-treated and hormone-naive Japanese PCa patients. Moreover, ADT did not significantly increase the prevalence of osteoporosis in this Japanese population.